DDInter664 DDInter1763
An ergot alkaloid with uterine and vascular smooth muscle contractile properties.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Ergometrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Ergometrine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Ergometrine {u} (Compound) downregulates {v} (Gene) PTPRK
PTPRK {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Ergometrine {u} (Compound) upregulates {v} (Gene) MAL
MAL {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Ergometrine {u} (Compound) causes {v} (Side Effect) Haematuria
Haematuria {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Ergometrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Ergometrine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Ergometrine {u} (Compound) downregulates {v} (Gene) PTPRK
PTPRK {u} (Gene) regulates {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Ergometrine {u} (Compound) upregulates {v} (Gene) MAL
MAL {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Ergometrine {u} (Compound) causes {v} (Side Effect) Haematuria
Haematuria {u} (Side Effect) is caused by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Ergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Ergometrine (Compound) downregulates PTPRK (Gene) and PTPRK (Gene) is upregulated by Temsirolimus (Compound)
Ergometrine (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Temsirolimus (Compound)
Ergometrine (Compound) causes Haematuria (Side Effect) and Haematuria (Side Effect) is caused by Temsirolimus (Compound)
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Ergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Ergometrine (Compound) downregulates PTPRK (Gene) and PTPRK (Gene) regulates CES1 (Gene) and CES1 (Gene) is upregulated by Temsirolimus (Compound)
Ergometrine (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Ergometrine (Compound) causes Haematuria (Side Effect) and Haematuria (Side Effect) is caused by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)